GYNECOLOGIC CANCERS

Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD

Bradley J. Monk, MD, discusses his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Shitanshu Uppal, MD, discusses the critical challenges to research and treatment advances in cervical and endometrial cancer.

Shana Wingo, MD, discusses advancements being made in the field of surgery for patients with gynecologic cancers.

Dana Chase, MD, discusses the potential for immunotherapy in recurrent endometrial cancer, as well as the lack of progress made thus far in endometrial cancer and other rare cancer types.

Elizabeth Swisher, MD, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Mike Janicek, MD,&nbsp;sheds light on why physicians are slow to educate patients on genetic testing, the detection of genes aside from <em>BRCA1/2</em>, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Lyndsay J. Willmott, MD, discusses how PARP inhibitor approvals have impacted clinical practice and patient outcomes and quality of life in ovarian cancer.

Heather Dalton, MD, discusses&nbsp;first-line treatment options currently available for patients, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

The IDO1 inhibitor BMS-986205 had &quot;best-in-class&quot; activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced tumors in a phase I/IIa study.

BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with <em>HER2</em>-mutant advanced cancers, according to findings from the phase II SUMMIT study presented at the 2017 AACR Annual Meeting.

A recent study found 12 new genetic variants were found that increase the risk of developing the disease and confirmed the association of 18 previously discovered variants.

The FDA has granted a priority review to a supplemental biologics license application (sBLA) supporting the conversion of the accelerated approval of blinatumomab (Blincyto) to a full approval as a treatment for patients with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Tisagenlecleucel-T (CTL019) has been granted a priority review designation by the FDA as a treatment for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia.

A new drug application (NDA) for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer has been granted a priority review by the FDA.

The PARP inhibitor niraparib (Zejula) has been approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Steven J. Skates, PhD, discusses&nbsp;a study on early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm (ROCA), in which CA125 was tested in women with high risk who chose to postpone surgery.

Stephan Grupp, MD, PhD, discusses results of the&nbsp;phase II ELIANA study&nbsp;and the next steps with CAR T-cell therapy in ALL.

Emma L. Barber, MD, discusses&nbsp;her research into neoadjuvant chemotherapy for ovarian cancer and its effect on hospital readmission rates.

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.